Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of PF-06954522 in Healthy Adults
NCT06003777Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06954522 in type 2 diabetes mellitus (T2DM) and obesity (3 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Hematology Laboratory Test Abnormalities and 4 more. Started Aug 2023; status: completed.
02
Drugs
PF-06954522
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06003777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003777.